347 related articles for article (PubMed ID: 29413175)
1. Sirtuins as Modifiers of Huntington's Disease (HD) Pathology.
Neo SH; Tang BL
Prog Mol Biol Transl Sci; 2018; 154():105-145. PubMed ID: 29413175
[TBL] [Abstract][Full Text] [Related]
2. Sirtuins as modifiers of Parkinson's disease pathology.
Tang BL
J Neurosci Res; 2017 Apr; 95(4):930-942. PubMed ID: 27402490
[TBL] [Abstract][Full Text] [Related]
3. Huntington's disease: the past, present, and future search for disease modifiers.
Clabough EB
Yale J Biol Med; 2013 Jun; 86(2):217-33. PubMed ID: 23766742
[TBL] [Abstract][Full Text] [Related]
4. A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease.
Smith MR; Syed A; Lukacsovich T; Purcell J; Barbaro BA; Worthge SA; Wei SR; Pollio G; Magnoni L; Scali C; Massai L; Franceschini D; Camarri M; Gianfriddo M; Diodato E; Thomas R; Gokce O; Tabrizi SJ; Caricasole A; Landwehrmeyer B; Menalled L; Murphy C; Ramboz S; Luthi-Carter R; Westerberg G; Marsh JL
Hum Mol Genet; 2014 Jun; 23(11):2995-3007. PubMed ID: 24436303
[TBL] [Abstract][Full Text] [Related]
5. HAP40 is a conserved central regulator of Huntingtin and a potential modulator of Huntington's disease pathogenesis.
Xu S; Li G; Ye X; Chen D; Chen Z; Xu Z; Daniele M; Tambone S; Ceccacci A; Tomei L; Ye L; Yu Y; Solbach A; Farmer SM; Stimming EF; McAllister G; Marchionini DM; Zhang S
PLoS Genet; 2022 Jul; 18(7):e1010302. PubMed ID: 35853002
[TBL] [Abstract][Full Text] [Related]
6. Murine Models of Huntington's Disease for Evaluating Therapeutics.
Kosior N; Leavitt BR
Methods Mol Biol; 2018; 1780():179-207. PubMed ID: 29856020
[TBL] [Abstract][Full Text] [Related]
7. Towards a comprehensive understanding of the contributions of mitochondrial dysfunction and oxidative stress in the pathogenesis and pathophysiology of Huntington's disease.
Tobore TO
J Neurosci Res; 2019 Nov; 97(11):1455-1468. PubMed ID: 31304621
[TBL] [Abstract][Full Text] [Related]
8. Molecular Pathogenesis in Huntington's Disease.
Illarioshkin SN; Klyushnikov SA; Vigont VA; Seliverstov YA; Kaznacheyeva EV
Biochemistry (Mosc); 2018 Sep; 83(9):1030-1039. PubMed ID: 30472941
[TBL] [Abstract][Full Text] [Related]
9. Clinical Features of Huntington's Disease.
Ghosh R; Tabrizi SJ
Adv Exp Med Biol; 2018; 1049():1-28. PubMed ID: 29427096
[TBL] [Abstract][Full Text] [Related]
10. Targeting sirtuin-1 in Huntington's disease: rationale and current status.
Duan W
CNS Drugs; 2013 May; 27(5):345-52. PubMed ID: 23549885
[TBL] [Abstract][Full Text] [Related]
11. Huntington's disease: molecular basis of neurodegeneration.
Rubinsztein DC; Carmichael J
Expert Rev Mol Med; 2003 Aug; 5(20):1-21. PubMed ID: 14585171
[TBL] [Abstract][Full Text] [Related]
12. Unconventional Secretion and Intercellular Transfer of Mutant Huntingtin.
Tang BL
Cells; 2018 Jun; 7(6):. PubMed ID: 29904030
[TBL] [Abstract][Full Text] [Related]
13. Role of Phosphodiesterases in Huntington's Disease.
Fusco FR; Paldino E
Adv Neurobiol; 2017; 17():285-304. PubMed ID: 28956337
[TBL] [Abstract][Full Text] [Related]
14. Sirtuins: double players in Huntington's disease.
Naia L; Rego AC
Biochim Biophys Acta; 2015 Oct; 1852(10 Pt A):2183-94. PubMed ID: 26163995
[TBL] [Abstract][Full Text] [Related]
15. Effect of 3-nitropropionic acid on sirtuin gene expression in Sirt3 deficient mice.
Horváth O; Klivényi P
Neurosci Lett; 2024 Jun; 836():137882. PubMed ID: 38909839
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial SIRT3 confers neuroprotection in Huntington's disease by regulation of oxidative challenges and mitochondrial dynamics.
Naia L; Carmo C; Campesan S; Fão L; Cotton VE; Valero J; Lopes C; Rosenstock TR; Giorgini F; Rego AC
Free Radic Biol Med; 2021 Feb; 163():163-179. PubMed ID: 33285261
[TBL] [Abstract][Full Text] [Related]
17. Molecular mediators, environmental modulators and experience-dependent synaptic dysfunction in Huntington's disease.
Hannan AJ
Acta Biochim Pol; 2004; 51(2):415-30. PubMed ID: 15218539
[TBL] [Abstract][Full Text] [Related]
18. Pathological mechanisms in Huntington's disease and other polyglutamine expansion diseases.
Lunkes A; Trottier Y; Mandel JL
Essays Biochem; 1998; 33():149-63. PubMed ID: 10488448
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of disease: Histone modifications in Huntington's disease.
Sadri-Vakili G; Cha JH
Nat Clin Pract Neurol; 2006 Jun; 2(6):330-8. PubMed ID: 16932577
[TBL] [Abstract][Full Text] [Related]
20. Selective neuronal degeneration in Huntington's disease.
Cowan CM; Raymond LA
Curr Top Dev Biol; 2006; 75():25-71. PubMed ID: 16984809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
